FDA Adverse Event Malfunction Summary report: N

I-STAT EC4+ CARTRIDGE

MDR report key: 8522245 · Received April 17, 2019

Report

Report Number
2245578-2019-00103
Event Type
Malfunction
Date Received
April 17, 2019
Date of Event
March 7, 2019
Report Date
May 28, 2019
Manufacturer
ABBOTT POINT OF CARE
Product Code
JGS
UDI-DI
10054749000095
PMA / PMN Number
K912387
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AZ, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

APOC INCIDENT #: (B)(4). THE INVESTIGATION WAS COMPLETED ON 05/24/2019. A REVIEW OF THE DEVICE HISTORY RECORD (DHR) CONFIRMED THE CARTRIDGE LOT MET FINISHED GOODS (FG) RELEASE CRITERIA. RETAINED TESTING MET THE ACCEPTANCE CRITERIA OUTLINED IN APPENDIX 1 OF Q04.01.003 REV. AD (PRODUCT COMPLAINT LEVEL 2 AND LEVEL 3 INVESTIGATION PROCEDURE). NO DEFICIENCY HAS BEEN DETERMINED FOR EC4+ LOT K18295.

Additional Manufacturer Narrative · 1

APOC INCIDENT #: (B)(4). APOC LABELING WILL BE EVALUATED DURING THE INVESTIGATION AS PERTAINING TO THE EVENT.

Description of Event or Problem · 1

ON (B)(6) 2019, ABBOTT POINT OF CARE WAS CONTACTED BY A CUSTOMER REGARDING I-STAT EC4+ CARTRIDGES THAT YIELDED A SUSPECTED DISCREPANT POTASSIUM RESULTS ON A (B)(6) YEAR OLD FEMALE PATIENT WITH END STAGE RENAL DISEASE. THERE WAS NO ADDITIONAL PATIENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT. METHOD: I-STAT, DATE: (B)(6) 2019, TESTED: 07:47, RESULTS: 5.8 MG/DL, SAMPLE: A. I-STAT, (B)(6) 2019, 08:53, 7.5 MG/DL, B. COLLECTION TIME NOT PROVIDED. THERE ARE NO INJURIES ASSOCIATED WITH THIS EVENT. AT THIS TIME THERE IS NO REASON TO SUSPECT A MALFUNCTION EXISTS. THE REPORTING DECISION WAS BASED ON LIMITED INFORMATION AVAILABLE THAT SUGGESTS THE PRODUCT WAS NOT PERFORMING WITHIN THE VARIABILITY OF THE ASSAY. THE INVESTIGATION IS UNDERWAY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
315368 I-STAT EC4+ CARTRIDGE EC4+ CARTRIDGE JGS ABBOTT POINT OF CARE NA K18295 10054749000095

Patients

Seq Age Sex Outcome Treatment
1 52 YR